PointState Capital LP trimmed its position in Loxo Oncology, Inc. (NASDAQ:LOXO) by 45.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,800 shares of the biopharmaceutical company’s stock after selling 41,800 shares during the quarter. PointState Capital LP owned approximately 0.17% of Loxo Oncology worth $3,993,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of Loxo Oncology by 12.1% in the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after buying an additional 472,814 shares during the period. BlackRock Inc. boosted its holdings in shares of Loxo Oncology by 20.6% in the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of Loxo Oncology by 50.2% in the second quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Loxo Oncology by 24.7% in the second quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock worth $73,351,000 after buying an additional 181,471 shares during the period. Finally, Driehaus Capital Management LLC boosted its holdings in shares of Loxo Oncology by 41.5% in the first quarter. Driehaus Capital Management LLC now owns 598,863 shares of the biopharmaceutical company’s stock worth $25,200,000 after buying an additional 175,587 shares during the period.

In related news, CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $73.56, for a total value of $1,103,400.00. Following the completion of the transaction, the chief executive officer now directly owns 196,207 shares in the company, valued at approximately $14,432,986.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Avi Z. Naider sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the transaction, the director now owns 154,118 shares of the company’s stock, valued at $13,870,620. The disclosure for this sale can be found here. Insiders sold a total of 84,896 shares of company stock valued at $6,865,562 over the last quarter. 44.40% of the stock is owned by insiders.

Loxo Oncology, Inc. (LOXO) traded down 0.56% during mid-day trading on Friday, hitting $87.66. 153,144 shares of the stock were exchanged. The firm has a 50-day moving average price of $82.91 and a 200-day moving average price of $65.91. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $95.92. The stock’s market capitalization is $2.62 billion.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same quarter last year, the business posted ($0.77) earnings per share. Equities analysts predict that Loxo Oncology, Inc. will post ($4.49) earnings per share for the current fiscal year.

Several research analysts have commented on the stock. BidaskClub cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price (up from $95.00) on shares of Loxo Oncology in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Thursday, August 3rd. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $94.00 target price (up from $71.00) on shares of Loxo Oncology in a report on Thursday, August 10th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Loxo Oncology currently has a consensus rating of “Buy” and an average target price of $76.31.

WARNING: “Loxo Oncology, Inc. (LOXO) Holdings Lowered by PointState Capital LP” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-holdings-lowered-by-pointstate-capital-lp/1615663.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.